Mary Beth Blauwet - Concepedia

Author

Mary Beth Blauwet

Also Known As

Blauwet, Mary Beth, Gettes, Leonard, M B Blauwet, M. B. Blauwet, M.B. Blauwet, Mary B. Blauwet, Mary Beth Blauwet, Natalie Boone, Patterson, James Herbert

Publications

1.3K

Citations

H-Index

Concepts

All Affiliations

Astellas Pharma (United States)Royal Hallamshire Hospital Imperial College London Astellas Pharma (Netherlands)Astellas Pharma (United Kingdom)

About

Mary Beth Blauwet is an author at Astellas Pharma (United States) specializing in medicine, cardiology, and cardiovascular disease.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	5	5	407
2	Health Sciences	2	2	66
3	Exercise Physiology	2	2	66
4	Gender Studies	1	1	291
5	Kinesiology	1	1	50

Mary Beth Blauwet

Publications

1.1K

Citations

H-Index

Page 1

	Year	Citations
Relation Between Gender, Etiology and Survival in Patients With Symptomatic Heart Failure Kirkwood F. Adams, Stephanie H. Dunlap, Carla A. Sueta, Journal of the American College of Cardiology CardiomyopathyHeart FailureCardiovascular DiseaseGender StudiesDiastolic Function	1996	291
Mirabegron for the treatment of overactive bladder: a prespecified pooled efficacy analysis and pooled safety analysis of three randomised, double‐blind, placebo‐controlled, phase <scp>III</scp> studies V. Khullar, Philip E.V. van Kerrebroeck, Sender Herschorn, International Journal of Clinical Practice	2013	206
Safety and tolerability of the β<sub>3</sub>‐adrenoceptor agonist mirabegron, for the treatment of overactive bladder: results of a prospective pooled analysis of three 12‐week randomised Phase III trials and of a 1‐year randomised Phase III trial Christopher R. Chapple, C. Walters, Mary Beth Blauwet, International Journal of Clinical Practice	2014	83
Effect of acute magnesium administration on the frequency of ventricular arrhythmia in patients with heart failure. Carla A. Sueta, S. W. Clarke, S Dunlap, Circulation	1994	70
Efficacy of mirabegron in patients with and without prior antimuscarinic therapy for overactive bladder: a post hoc analysis of a randomized European-Australian Phase 3 trial Vik Khullar, J. Cambronero, J.C. Angulo, BMC Urology	2013	69
Efficacy and safety of daily mirabegron 50 mg in male patients with overactive bladder: a critical analysis of five phase III studies Andrea Tubaro, José E. Batista, Victor W. Νitti, Therapeutic Advances in Urology	2017	56
Identification of false positive exercise tests with use of electrocardiographic criteria: A possible role for atrial repolarization waves Peter M. Sapin, Gary G. Koch, Mary Beth Blauwet, Journal of the American College of Cardiology Atrial Repolarization WavesElectrophysiological EvaluationKinesiologyHealth SciencesCardiovascular Disease	1991	50
Mirabegron 50 mg once‐daily for the treatment of symptoms of overactive bladder: An overview of efficacy and tolerability over 12 weeks and 1 year Christopher R. Chapple, Steven A. Kaplan, David Mitcheson, International Journal of Urology	2014	45
886 THE EFFICACY AND TOLERABILITY OF MIRABEGRON IN PATIENTS WITH OVERACTIVE BLADDER – RESULTS FROM A EUROPEAN–AUSTRALIAN PHASE III TRIAL V. Khullar, J. Cambronero, Peter Ströberg, European Urology Supplements Urological ResearchUrologyVoiding DysfunctionPharmacotherapyUrogynecology	2011	37
Tropomyosin-related kinase A (TrkA) inhibition for the treatment of painful knee osteoarthritis: results from a randomized controlled phase 2a trial Fiona E. Watt, Mary Beth Blauwet, A. Fakhoury, Osteoarthritis and Cartilage	2019	33

Page 1